Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interferon Beta Use and Disability Prevention in Relapsing-Remitting Multiple Sclerosis.
Capture, crawl, cross: the T cell code to breach the blood-brain barriers.
SIGLEC1 and SIGLEC7 expression in circulating monocytes of patients with multiple sclerosis.
A signal-to-noise-ratio-based analysis of multifocal visual-evoked potentials in multiple sclerosis risk assessment.
Venocentric Lesions: An MRI Marker of MS?
Secukinumab (AIN457) showed superiority over Enbrel® in clearing skin, according to pivotal Novartis Phase III psoriasis results at EADV
Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice.
Importance of Human Leukocyte Antigen (HLA) Class I and II Alleles on the Risk of Multiple Sclerosis.
Analysis of the Paired TCR α- and β-chains of Single Human T Cells.
Preventive healthcare use among males with multiple sclerosis.
Evaluating medically at-risk drivers: a survey of assessment practices in Canada.
Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.
Prolongation of survival of rat cardiac allografts by T cell vaccination.
Abstracts of ECTRIMS (Congress of the European Committee for Treatment and Research in Multiple Sclerosis) 2013. October 2-5, 2013. Copenhagen, Denmark.
Interferon-β Suppresses Murine Th1 Cell Function in the Absence of Antigen-Presenting Cells.
Pediatric multiple sclerosis in Venezuela.
Different mechanisms underlying changes in excitability of peripheral nerve sensory and motor axons in multiple sclerosis.
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases.
Overview of the biology of type I interferons.
Stelara (Ustekinumab) receives FDA Approval for Treatment of Moderate to Severe Plaque Psoriasis with Four-Times-A-Year Maintenance Dosing
Recommendations for the management of multiple sclerosis relapses.
Neuromyelitis Optica With Onset in Childhood and Adolescence.
Glial contributions to neural function and disease.
Disease Suppression Persists With Ozanimod at 72 Weeks in MS

Pages